文献速递临床免疫分子诊断

人群规模新冠血清学:唾液中SARS-CoV-2特异性抗体应答

COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva.
PubMed 文献 · J Clin Microbiol · 2020-12-17

研究基于Luminex技术建立包含12种冠状病毒抗原的多重SARS-CoV-2抗体免疫分析,检测确诊COVID-19病例及疫情前样本的唾液和血清中IgG、IgA、IgM。匹配唾液与血清IgG应答显著相关(n=28);唾液抗N IgG在症状出现后>14天采样的24/24例RT-PCR确诊者中均阳性(灵敏度100%),抗RBD IgG特异性100%;唾液IgG动力学与血液一致,多数在约10天血清阳转,联合N和S抗原IgG算法在10天即达100%诊断准确性。

要点

  • 唾液抗N IgG对症状出现后>14天确诊者灵敏度100%(24/24)。
  • 唾液抗RBD IgG特异性达100%。
  • 联合N和S抗原IgG算法在症状出现后10天诊断准确性100%。

核心结论

  • 唾液抗体检测可作为血液抗体检测的非侵入性、可扩展替代方案用于人群SARS-CoV-2感染和血清阳性监测。

研究设计与样本

  • 开发基于Luminex技术的多重SARS-CoV-2抗体免疫分析,包含12种冠状病毒抗原(主要源自SARS-CoV-2核衣壳N和刺突S)。
  • 检测确诊COVID-19病例及疫情前时代采集的唾液和血清样本中针对抗原面板的IgG、IgA和IgM。
  • 匹配唾液和血清IgG应答样本n=28。

主要发现

  • 匹配唾液和血清IgG应答显著相关(n=28)。
  • 唾液抗N IgG灵敏度最高(100%),在症状出现后>14天采样的24/24例RT-PCR确诊COVID-19病例中阳性。
  • 唾液抗RBD IgG特异性100%。
  • 唾液IgG时间动力学与血液一致,多数个体在症状出现后约10天血清阳转。
  • 联合N和S抗原IgG应答的算法在症状出现后10天即达高诊断准确性(100%)。

关键数值与推荐

  • 唾液抗N IgG灵敏度100%(24/24,症状出现后>14天RT-PCR确诊)。
  • 唾液抗RBD IgG特异性100%。
  • 联合N和S抗原IgG算法诊断准确性100%(症状出现后10天)。

临床怎么用

  • 可采用唾液抗体检测替代血液抗体检测进行人群SARS-CoV-2感染和血清阳性监测。
  • 优先采用联合N和S抗原IgG应答的算法以提高诊断准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic that has infected over 36 million and killed over 1 million people. Informed implementation of government public health policies depends on accurate data on SARS-CoV-2 immunity at a population scale. We hypothesized that detection of SARS-CoV-2 salivary antibodies could serve as a noninvasive alternative to serological testing for monitoring of SARS-CoV-2 infection and seropositivity at a population scale. We developed a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology that comprised 12 CoV antigens, mostly derived from SARS-CoV-2 nucleocapsid (N) and spike (S). Saliva and sera collected from confirmed coronavirus disease 2019 (COVID-19) cases and from the pre-COVID-19 era were tested for IgG, IgA, and IgM to the antigen panel. Matched saliva and serum IgG responses (n = 28) were significantly correlated. The salivary anti-N IgG response resulted in the highest sensitivity (100%), exhibiting a positive response in 24/24 reverse transcription-PCR (RT-PCR)-confirmed COVID-19 cases sampled at >14 days post-symptom onset (DPSO), whereas the salivary anti-receptor binding domain (RBD) IgG response yielded 100% specificity. Temporal kinetics of IgG in saliva were consistent with those observed in blood and indicated that most individuals seroconvert at around 10 DPSO. Algorithms employing a combination of the IgG responses to N and S antigens result in high diagnostic accuracy (100%) by as early as 10 DPSO. These results support the use of saliva-based antibody testing as a noninvasive and scalable alternative to blood-based antibody testing.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Pisanic N, Randad PR, Kruczynski K, et al. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. J Clin Microbiol. 2020. PMID: 33067270. doi:10.1128/JCM.02204-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。